Article

How Does Media Selection Impact Performance Testing Of Poorly Soluble Drugs?

iStock-1126056974-OSD-oral-solid-dose-tablet-capsule

The flexibility and convenience of oral drug delivery has made it the most commonly used dosage form in the pharmaceutical industry. However, the solubility of a drug in the gastrointestinal (GI) tract ― and, ultimately, its efficacy ― is highly dependent on its physicochemical properties and the patient’s GI fluid properties. Drug candidates identified as poorly soluble (i.e., Class II and IV in the biopharmaceutics classification system) require proper formulation with the most appropriate excipients to increase solubility, which is an issue for 70% to 80% of small molecules at the discovery stage.1 In vitro testing can help predict bioperformance but only if the right biorelevant dissolution media (BDM) is used by a company’s formulation experts.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: